title: [Prolactin and cancer of the breast. II. Prediction of the response to hormone treatment. The Minton test].
abstract: The prediction of the response to endocrine therapy in breast cancer is important. Although the estrogen receptor assay is a fundamental procedure to know hormone dependency in breast cancer, the changes produced in the serum prolactin level after administering L-dopa is a simple and reproducible method that can be used as alternative predictive test in some cases. This work shows that a 65 per 100 decrease or more in the L-dopa induced prolactin level prognosticates the existence of a hormone responsive tumor.
mesh_terms: D001943:Breast Neoplasms / Q000097:blood / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007980:Levodopa; D008525:Medroxyprogesterone / Q000627:therapeutic use; D010052:Ovariectomy; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D013629:Tamoxifen; D007980:Levodopa; D011388:Prolactin; D008525:Medroxyprogesterone
vernacular_title: Prolactina y cáncer de mama. II. Predicción de respuesta al tratamiento hormonal. Test de Minton.